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Objectives: To assess a bundled Antimicrobial Stewardship Program and its effect on mor-
tality.
Data: Eight months of clinical electronic medical records and Antimicrobial Stewardship
Program registries were used as source of data.
Method: This is a historical cohort study conducted in a Brazilian University Hospital. Eligible
patients were admitted to general wards or intensive care units and had an antimicrobial
therapy prescribed and assessed by different strategies: Bundled Antimicrobial Stewardship
Program (bundled intervention consisted of clinical pharmacist chart review, discussion
with microbiologist and infectious disease physicians, local education and continuous
follow-up) or Conventional Antimicrobial Stewardship Program (clinical pharmacist chart
review and discussion with infectious disease physician). Primary outcome from this study
was  30-day mortality, which was compared between groups, by using Kaplan–Meier survival
curve and log-rank test. Other outcomes included Deﬁned Daily Doses per 1000 patient-days
and occurrence of resistant bacteria.
Results: From 533 patients, 491 were eligible for the study, of which 191 patients were
included to Antimicrobial Stewardship Program and 300 to Conventional strategy. In gen-
eral,  they were likely to be male and age was similar in groups (58.9 vs 55.5 years, p = 0.38).
Likewise, Charlson Comorbidity Index was not statistically different between groups (2.6 vs
2.7,  p = 0.2). Bloodstream site infections were frequently diagnosed in both groups (30.89%
vs  26%, p = 0.24). Other less common sites of infections were central nervous system and
lungs. The ASP group had higher survival rates (p < 0.01) and the risk difference was 10.8%
(95%  CI: 2.41–19.14). There were less Deﬁned Daily Doses per 1000 patient-days (417 vs 557.2,
p  < 0.05) and higher rates of resistant bacteria identiﬁed in the ASP group (83% vs 17%).Conclusion: Bundled ASP was the most effective strategy, with reduced mortality and Deﬁned
 patieDaily Doses per 1000∗ Corresponding author.
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ackground
ntimicrobial Stewardship Programs (ASP) seek to optimize
linical outcomes and to reduce unwanted events related to
nappropriate use of antimicrobial drug therapy (ADT).1,2
According to the Infectious Disease Society of Amer-
ca and Society for Healthcare Epidemiology of America,1
he collaboration between an Infectious Diseases Medical
octor (ID MD), a clinical pharmacist, and other profession-
ls improves patient outcomes by conducting prospective
udits/feedback, formulary restriction, local education, imple-
enting evidence-based guidelines, de-escalation and esca-
ation of ADT, dose optimization, and intravenous-to-oral
herapy switch.
Common outcomes used to assess the effectiveness of
tewardship Programs include speciﬁc indicators such as drug
aste, days of therapy, Deﬁned Daily Doses (DDDs), reduc-
ion of antimicrobial resistance, and rate of Clostridium difﬁcile
nfections.3,4 ASP-related research has also reported positive
ffects on hospital length of stay and mortality,5,6 but still they
re scarce in international literature because such outcomes
an be inﬂuenced by multiple confounders.
Recently, one systematic review has evaluated a single
ntervention – ADT de-escalating – on mortality.7 In fact, such
vidence was poorly planned and it does not illustrate what
tewardship Programs are all about. Despite the importance
f ADT de-escalating and its large applicability to preserve
arge spectrum antibiotics, other interventions such as switch
herapy (intravenous-to-oral) and ADT initiation are largely
erformed by Stewardships.8 Current research have evidenced
hat they play a role in reducing resistant bacteria and other
ndesired events.8–11
There is a demand to conduct ASP researches that illustrate
hat is performed during daily clinical practice. Notwith-
tanding, ID societies1,2 endorse the need to assess whether
 “bundled” ASP strategy, with as many  as possible interven-
ions, improves patients’ outcomes.2
bjectives
his research aimed to assess the effects of a bundled ASP
trategy on 30-day mortality. Secondary objectives from this
tudy assessed bundled ASP effects on DDD and occurrence
f resistant bacteria.
ethods
tudy  design  and  settinghis is a retrospective cohort study conducted in a Brazilian
ublic university hospital with 550 beds and an average of 60%
ccupation.
This hospital has a ﬁve day/week ASP and the core mem-
ers from this team include two ID physicians (preceptor and
D resident) and one pharmacist (resident).5;1 9(3):246–252 247
Patients
From February to September 2013, patients who  were more
than 18 years old were included in this study when admitted
to adult general ward or intensive care unit (ICU). To meet eligi-
bility criteria, they also needed to have a drug-related problem
in their ADT prescription evaluated by a clinical pharmacist at
the ﬁrst or second day of drug therapy. Exclusion criteria for
this study were: admission to other wards (cardiac, oncology
and hematology wards and other specialty units); patients not
assessed by clinical pharmacist; non-acceptance of interven-
tions suggested by ASP.
During the study period, patients were assigned to different
Stewardship Programs according to human resources avail-
ability. Thereby, two strategies were concomitantly performed
and patients could receive either a conventional ASP or a bun-
dled ASP.
Bundled strategy consisted in daily clinical pharmacist
ADT problems screening by using chart reviews, lab results
and electronic system review; discussion with ID MD  and
microbiologist (i.e. daily visits to laboratory to discuss possi-
bilities to narrowing or increasing antibiotics spectrum); local
education to prescribers to improve drug therapy use; and
provide continuous follow-up (until clinical resolution or dis-
charge, when applicable).
Conventional strategy consisted of a passive ASP, whereby
a clinical pharmacist performed the same drug therapy prob-
lems screening and discussed each case with ID physicians.
Whenever an intervention was necessary, a phone was used
to communicate with prescribers.
Data  collection,  baseline  characteristics  and  outcomes
One pharmacist (LMO) collected data from ASP interventions
registries, hospital’s medical record and pharmacy dispensing
registries.
To compare baseline ASP strategies, we  considered demo-
graphic variables (age and sex), clinical conditions (primary
site of infection, Charlson’s Comorbidity Index – CCI, admis-
sion to ICU or general ward)12 and days of follow-up/per
patient.
The primary outcome from this study was 30-day mor-
tality, which was compared between groups. Other assessed
outcomes included: DDD reduction, interventions performed
to improve ADT and occurrence of resistant bacteria in blood
cultures. In order to assess such outcomes the following deﬁ-
nitions were used:
• 30-day mortality: time period since patient assessment by
conventional or bundled ASP strategy, till discharge (sur-
vive) or event of death.
• DDD was expressed as DDD/thousand patient-days and
was calculated according to World Health Organization
criteria.13• Resistant bacteria were all types of isolated organisms that
had a documented drug resistance in a sterile biological
sample (only blood culture was considered). We did not con-
sider in this outcome drug sensitive bacteria.
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Finally, we conducted a subgroup analysis by including all
patients who had not accepted intervention by ASP to analyze
the impact on mortality.
Study  sample
The calculated sample size for the present study was 186
patients in each study arm based on a previous study14 and
considering a relative risk of 0.57 on mortality, two-sided
hypothesis, 5% alpha and 80% power. We  chose this study
because it was conducted in a critical care setting, which is
also part of our inclusion criteria. Moreover, such a study was
also conducted in a Brazilian hospital and showed impact on
mortality.
Data  analysis  and  statistical  methods
Descriptive statistics were used to analyze continuous and
dichotomous variables. Inferential analyses were performed
to compare patient characteristics, whereby continuous vari-
ables were assessed with t-test (normal curve assumed with
Komolgorov–Smirnov test) and proportion variables were ana-
lyzed with chi-square or Fisher’s exact test, as adequate.
To assess the primary outcome, a survival analysis
(non-parametric Kaplan–Meier method and log-rank test)
compared the occurrence of fatal events between groups.
We  also determined point estimate values, such as absolute
risk reduction (ARR), relative risk (RR), number needed to
treat (NNT) and 95% conﬁdence intervals (CI). Incidence rates
(IR) of 30-day mortality per thousand patient-days were also
reported by means of comparison to other epidemiological
studies.
At last, as we  did not balance patients between groups,
different baseline characteristics could inﬂuence the pri-
mary  outcome. Therefore, all critical variables at baseline
(p < 0.2) were included in a Cox proportional-hazards regres-
sion. Selected variables were included one-by-one in the
multivariate analysis model and covariates were controlled by
variables that had a p-value variation greater than 0.1.
All statistical analyses were conducted using SPSS v. 20.0
and considered a two-sided hypothesis test and 5% probability
of a type I error. All p-values lower than 0.05 were considered
statistically signiﬁcant.
Ethical  issues
The local Bioethics Committee, which complies with
Helsinki’s Declaration, approved this study and the certiﬁcate
number of analysis is CAAE 26619414.2.0000.0096. Lastly, we
used the STROBE Statement to write this manuscript and
provide adequate reporting.15
Results
Patient  characteristicsDuring the study period, pharmacists assessed more  than
3000 patients and 533 had undergone clinical pharmacists DRP
screening and had ADT problems. Of those, 191 received theFig. 1 – Survival curves of different ASP strategies.
bundled ASP Strategy and 300 patients received the conven-
tional ASP. Other 42 patients did not have their drug therapy
modiﬁed as suggested by the ASP team, and therefore were
analyzed separately (Table 2).
In summary, there were predominantly male patients, who
had a similar age (58.9 vs 55.5 years, p = 0.17) and CCI score (2.6
vs 2.7, p = 0.2). As expected, ICU patients had greater CCI scores
than patients in general wards (Table 1).
The most common sites of infection in both ASP groups
were, respectively, bloodstream (30.9% vs 26%, p = 0.19), respi-
ratory (28.3% vs 38%, p < 0.03), and urinary tract infections
(14.1% vs 6.7%, p = 0.01). Other less common sites of infec-
tion were central nervous system and ventilator-associated
pneumonia (VAP).
Primary  outcome:  crude  mortality  and  group  comparison
In general, 166 (34%) patients experienced a fatal event and
the overall 30-day mortality incidence was 1.6 deaths per
100 patient-days. There was a signiﬁcant difference between
group rates (1.1 vs 1.9 deaths/100 patient-days, p = 0.002). To
calculate the incidence rate denominator, follow-up between
groups ought to be statistically the same, which was conﬁrmed
with a non-signiﬁcant p-value of 0.23 (Table 1).
Survival analysis showed that 30-day mortality was lower
with bundled ASP (p < 0.01) (Fig. 1). The RR was 28% lower
in the bundled ASP group (RR = 0.72, 95% CI 0.54–0.94) and
we observed an absolute risk reduction of 10.7% (95% CI
2.41–19.14), which means that for every nine patients who
receive ASP, one will beneﬁt from this intervention (NNT = 9.28,
95% CI 5.22–41.54) (Fig. 2).
Secondary  outcomes
The average DDD per 1000 patient-days was signiﬁcantly lower
in the bundled ASP group: 417 (±56.1) vs 557.2 (±10.25), p < 0.01.There was a higher rate of resistant bacteria in the Bun-
dled ASP group (83% vs 17%), and commonly isolated bacteria
were K. pneumonia (either one drug resistant, carbapenemase
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Table 1 – Patient characteristics.
Characteristics Bundled ASP (n = 191) Conventional ASP (n = 300) p-value
No. of patients % No. of patients %
Age, in years
Mean (sd)
58.9  (18.3) 55.5 (17.3) 0.38
Sex, female 79 41.3 143 47.7 0.17*
General ward 54 28.3 68 22.7 0.33
Intensive care units 137 71.7 232 77.3 0.2*
Primary infection site
Bloodstream site 60 31.4 78 26 0.19*
Central nervous system 6 3.1 6 2 0.43
Gastrointestinal 25 13.1 44 14.7 0.62
Skin and soft tissue 14 7.3 23 7.7 0.89
Respiratory tract 54 28.3 114 38 0.03*
Ventilation associated 5 2.6 15 5 0.19*
Urinary tract 27 14.2 20 6.6 0.01*
Charlson Comorbidity
Index
Mean (sd)
2.6  (2.3) 2.7 (2.4) 0.2*
General ward
Mean (sd)
2.6  (2.4) 2.6 (2.4) –
Intensive care units
Mean (sd)
2.8  (1.8) 3.0 (2.3) –
Days of follow-up
Mean (sd)
25.9  (32.7) 19.5 (21.1) 0.23
30-Day mortality 52 (27.2) 114 (38) <0.01
Intensive care units 42 (21.9) 99 (33) <0.01
General ward 10 (5.2) 15 (5) <0.01
Abbreviations: sd, standard deviation; 95% CI, 95% conﬁdence interval.
Data are n (%) unless otherwise stated.
∗ Considered to be included in the Cox regression.
Table 2 – Effects of non-accepting ASP intervention.
Bundled
vs
conventional ASP
(total = 491 patients)
Bundled + non-accepted
interventions
vs
observation
(total = 533 patients)
ARR 10.8% (95% CI 2.4–19.1) 8.82% (95% CI 0.8–16.8)
o
m
N
i
o
e
p
h
8
B
S
w
0%
11%
(26)
39%
(89)
28%
(63)
8%
(18)
8%
 (18)6%
(13)
5%
10%
15%
20%
25%
30%
40%
50%
45%
35%
AD
T c
ha
ng
e
Do
sa
ge
Su
sp
en
sio
n
Ini
tia
tio
n
Es
ca
lat
ion
De
-e
sc
ala
tio
n
Fig. 2 – Interventions performed to improve Antimicrobial
Drug Therapy (ADT). Notes:  There were  14 interventions
performed by ASP after discussing laboratory preliminary
results (Table 4), such as morphology, culture or
biochemistry ﬁndings, whereby 8 were  antimicrobial
initiation, 4 escalations, and 2 de-escalations. “ADT
Change” accounted for IV/PO switch and same spectrum
modiﬁcation (vancomycin → daptomycin).RR 0.72 (95% CI 0.54–0.94) 0.77 (95% CI 0.6–0.98)
r extended spectrum beta-lactamase positive), followed by
ethicillin-resistant negative coagulase Staphylococcus (MR
CS) (Table 4).
There were 227 accepted interventions, which consisted
n changing ADT (11%), improving dosage (39%), interruption
f treatment (28%), initiation of ADT (8%), escalation or de-
scalation (6% and 8%, respectively) (Table 2).
Lastly, in a subgroup analysis considering the 42 excluded
atients, who  had not accepted an intervention, we  would
ave observed a 2% decrease in the efﬁcacy of ASP (10.8% vs
.8%) and a 6% reduction in RR (RR, 0.72–0.77) (Table 2).
aseline  characteristics  and  impact  on  30-day  mortalityix covariates (sex, CCI, UTI, VAP, RT, and admission to ICU)
ere included in the multivariate model (see bivariate analysisin Table 1) to assess whether they could inﬂuence primary
outcome.Cox regression determined that two variables could inde-
pendently predict the risk of death: CCI and admission to ICU
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Table 3 – Independent predictors of 30-day mortality
after Cox proportional-hazards regression.
Variable p-value aHR 95% CI
Sex 0.917 0.89 0.75–1.39
BSI 0.040 0.64 0.41–0.98
RT 0.974 1.36 0.68–1.49
UTI 0.939 1.05 0.52–1.83
VAP 0.220 0.56 0.78–2.96
Charlson Comorbidity Index* 0.003 1.09 1.03–1.16
Admission to ICU* 0.005 0.93 0.89–0.98
Abbreviations:  aHR, adjusted Hazard Ratio; BSI, Blood Site Infections;
RT, Respiratory Tract Infection; UTI, Urinary Tract Infection; VAP,
Ventilator-Associated Pneumonia; SE, standard error; ICU; Inten-
sive Care Unit; 95% CI, 95% conﬁdence interval.
Intensive Care Units was changed to “Admission to ICU”, to facilitate
reading.
∗ Covariates with statistical signiﬁcance.
(Table 3) may have inﬂuenced 30-day mortality and they were
slightly higher in conventional ASP.
Discussion
Mortality  reduction
This study assessed the effectiveness of a bundled ASP by
using mortality and other relevant outcomes such as DDD
reduction, occurrence of resistant bacteria, and interventions
performed to improve ADT. The 10% absolute risk reduction
between groups can be considered as an important clinical
effect. Previous studies14,16 used regression techniques or dif-
ferent periods to assess the effects of ASP implementation,
which is different from our study design; we compared differ-
ent ASP strategies.
Nonetheless, we  conducted a retrospective cohort study
and future prospective investigations – randomized controlled
trials – would be important to answer whether different types
of ASP strategies result in different outcomes. This informa-
tion should be endorsed by two other ﬁndings in our study:
• The RR (0.72, 95% CI 0.54–0.94) was higher if compared to a
previous research (RR = 0.57)14 and we  attribute this differ-
ence to small but important effectiveness of non-bundled
strategy.
• In multivariate analysis, CCI and admission to ICU
were considered risk factors and could have inﬂu-
enced 30-day mortality between groups. Propensity scores
could not improve the balance between the two groups
because all patients that received both strategies were
included.
When we  input patients who  did not accept an inter-
vention by bundled ASP (previously excluded from study),
we observed increased mortality rates. Outcomes may be
directly impacted by accepting or not ASP suggestions.
Therefore, non-acceptance of an ASP intervention may
be discouraged, and institutions with low rates of ASP
acceptance should delineate strategies to change this risky
behavior. 1 5;1  9(3):246–252
Lower  use  of  antimicrobial  drug  therapy
Regarding DDD reduction, A-II level evidence from interna-
tional guidelines1 indicates that ASP interventions reduce
unnecessary ADT prescription. Previously, a multicenter (9
hospitals) cohort study16 showed that 206 (38%) out of 542
patients received inappropriate use of ADT.  Such rate of
inadequate ADT reassures why bundled strategy may have
performed so many  interventions to optimize antibiotics use.
In our study, renal function dose adjustments (dose
reduction) and drug interruption were the most prevalent
interventions and comprised almost 70% from all ADT opti-
mizations performed by the bundled strategy. For these
reasons, we believed that bundled ASP interventions were
directly responsible for DDD reduction.
Although this scenario suggests less antibiotics use and
cost reduction, it is important to remember that DDD decrease
neither implies global cost-savings nor cost-effectiveness, as it
only accounts for ADT consumption. Other variables should be
addressed to assess the impact of ASP on economic outcomes
– such as length of stay and human resource costs.
More  bacteria  identiﬁcation:  cause  or  consequence?
Interestingly, bundled ASP had more  positive blood cultures
than conventional ASP, both in general wards and ICU. We
believe that these ﬁndings are likely to be caused by bundled
ASP. In other words, local audits and continuous education to
physicians may have promoted bacteria identiﬁcation.
Because this study was not powered and designed for such
assessment, we did not make further assessments through
regression analysis, as this could lead to untrue statements.
However, other hypotheses that have been brought up from
these observations are: is the rate of microbial identiﬁcation
inﬂuenced by locally educating physicians and by better infec-
tious disease management? Does ASP intervention lead to
more  cultures? Does ASP stimulate more  accurate infection
diagnosis or does more  bacterial isolation ultimately leads to
reduced mortality?
Resistant bacteria were more  often identiﬁed in the
bundled ASP group, like resistant Klebsiella spp, including car-
bapenemase producers, methicillin-resistant staphylococci,
and resistant Acinetobacter baumanii. All of the aforementioned
microorganisms are associated with higher death rates17,18
and, even so, bundled ASP was associated with better out-
comes.
Limitations
This manuscript has several limitations. Firstly, this was a ret-
rospective study; thus, data collection and source of clinical
registries are natural drawbacks for these studies including:
incomplete data, censoring, and non-blinded data analy-
sis. We  preferred a cohort design instead of a clinical trial
because, in this preliminary assessment, we  had to investigate
whether different ASP strategies could impact patient out-
comes. Moreover, designing a proper randomized clinical trial
for antimicrobial stewardship is rather complicated, especially
for a prospective audit and feedback strategy; proper patient
allocation concealment and education-feedback process may
b r a z j i n f e c t d i s . 2 0 1 5;1 9(3):246–252 251
Table 4 – Resistant bacteria isolated from blood cultures according to wards and to groups.
Bacteria Bundled ASP Conventional ASP
ICU (n) Non-ICU (n) ICU (n) Non-ICU (n)
K. pneumoniae (KPC+ or ESBL) 6 – – –
NCS 5 1 – 2
A. baumanii (resistant) 5 – – –
NCS (MR) 3 – 1 –
S. aureus (MRSA) 3 – 1 1
P. aeruginosa 1 2 – –
E. cloacae – 1 – 1
E. faecalis – 1 – 1
B. cepacia 1 – – –
C. freundii – 1 – –
E. faecium (VRE) 1 – – –
E. aerogenes – 1 – –
K. pneumoniae – 1 – –
P. aeruginosa (resistant) 1 – – –
S. viridans 1 – – –
Total (42 isolated) 27 (64%) 8 (19%) 2(5%) 5 (12%)
Abbreviations: ICU, intensive care unit; KPC+, Carbapenemase resistance; ESBL, extended spectrum beta-lactamase; NCR MR, non-coagulase
methicillin-resistant Staphylococcus;  MRSA; methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci. Resistant A.
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ead to better antibiotic prescribing practices over time.19,20
uch method-related opportunities should be considered in
uture studies.
Secondly, “care bundles” of different antimicrobial stew-
rdship interventions are often implemented concurrently
i.e., education of prescribers, formulary restriction, prospec-
ive audit, and feedback).21 Therefore, considering also the
xistence of infection prevention bundles, researchers aim-
ng to tease out the contribution of each intervention.7 may
nd difﬁculties to isolate true clinical effects on patients’
utcomes. Nevertheless, the IDSA recommend researching
ragmatic and practice-oriented ASP,1 which was our choice
hen designing the present study.
Furthermore, our study design did not allow for quantiﬁ-
ation of the antimicrobial stewardship effects on bacterial
esistance, as it takes time for the beneﬁts to be evi-
ent. That is why the majority of published stewardship
apers adopted quasi-experimental designs: typically before
nd after implementation studies, where “treatment” allo-
ation and other potential confounding factors are not
ontrolled.1,22–24
We  observed a signiﬁcant difference between groups
egarding the rate of respiratory tract and urinary tract
nfections. Since multivariate analysis indicated that both
ites of infection were not independently associated with an
ncrease on 30-day mortality, we believe these differences
etween groups were due to imbalanced patients allocation.
f on one hand such statistical procedure would lead to bal-
nced groups, on the other hand in multivariate analysis
o assess whether group differences could predict primary
utcome only CCI and admission to ICU played a role on
0-day mortality. Thus, future studies should strongly con-
ider controlling for these two variables, although they were
nly signiﬁcant after accepting a p-value < 0.2 in univariate
nalysis.illins, aminoglycosides, or quinolones).
Finally, our study setting was a university hospital, where
there are resident rotations, so more  DRP may be found.
Moreover, professionals may be more  willing to accept inter-
ventions.
One should consider the external validity of our study
before implementing our results in distinct services or
comparing them with other investigations; this study was con-
ducted in a Latin American country.
Final  considerations
The bundled ASP proved to be an effective way to improve
antimicrobial drug therapy, by reducing 30-day mortality and
DDD/1000 patient-days. Moreover, CCI and admission to ICU
were likely to increase mortality, so patients with these risk
factors should receive more  attention in future ASP studies.
Worldwide, ASP implementation has risen in response
to the growing threat of antimicrobial resistance amidst
the diminishing pipeline of new antibiotics. We  believe
that antimicrobial stewardship will continue to evolve in
the upcoming decade, and among various interventions,
prospective audit and feedback will probably be the most
implemented strategy, in view of its clear advantages: particu-
larly, lack of prescribers’ opposition and prescribing behavior
modiﬁcation.25
Future researches should focus on evaluating the role and
ways to improve clinical effectiveness of different bundled
strategies, especially those interventions that may increase
the rate of bacteria isolation, which translates into correctly
selecting ADT to treat speciﬁc microorganisms. There is also
an urgent need to standardize outcomes as well as develop
novel study designs that can objectively assess antimicro-
bial stewardship interventions, despite the limitations and
opportunities inherent to ASPs heterogeneous structures and
process.
i s . 2 0
r
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2252  b r a z j i n f e c t d 
Funding
The Brazilian Ministry of Education provided a monthly schol-
arship to the ﬁrst author (LMO). The other authors have not
received any speciﬁc grant for this research.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
Acknowledgements
We  acknowledge the contribution of all professionals that
improved patient outcomes by dedicating their time to hos-
pital ASP. In addition, we thank the Brazilian Journal of
Infectious Disease double blind review process, which made
timely contributions to our manuscript.
 e  f  e  r  e  n  c  e  s
1. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases
Society of America and the Society for Healthcare
Epidemiology of America Guidelines for developing an
institutional program to enhance antimicrobial stewardship.
Clin Infect Dis. 2007;44:159–77.
2. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable
impact of a multidisciplinary antibiotic management
program conducted during 7 years. Infect Control Hosp
Epidemiol. 2003;24:699–706.
3. Lawton RM, Fridkin SK, Gaynes RP, McGowan JE. Practices to
improve antimicrobial use at 47 US hospitals: the status of
the  1997 SHEA/IDSA position paper recommendations. Infect
Control Hosp Epidemiol. 2000;21:256–9.
4. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN.
Decrease in nosocomial Clostridium difﬁcile-associated
diarrhea by restricting clindamycin use. Ann Intern Med.
1994;120:272–7.
5. Yeo CL, Wu  JE, Chung GWT,  Chan DSG, Chen HH, Hsu LY.
Antimicrobial stewardship auditing of patients reviewed by
infectious diseases physicians in a tertiary university
hospital. Antimicrobial Resist Infect Control. 2013;2:29.
6. Rosa RG, Goldani LZ, Santos RP. Association between
adherence to an antimicrobial stewardship program and
mortality among hospitalised cancer patients with febrile
neutropaenia: a prospective cohort study. BMC Infect Dis.
2014;14:286.
7. Silva BN, Andriolo RB, Atallah AN, Salomão R. De-escalation
of  antimicrobial treatment for adults with sepsis, severe
sepsis or septic shock. Cochrane Database Syst Rev.
2013;3:CD007934.
8. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene
JG.  A prospective randomized study of inpatient antibiotics
for community-acquired pneumonia. The optimal duration of
therapy. Chest. 1996;110:965–71.9. Shojania KG, Yokoe D, Platt R, Fiskio J, Maluf N, Bates DW.
Reducing vancomycin use utilizing a computer guideline:
results of a randomized controlled trial. J Am Med Inform
Assoc. 1998;5:554–62.
2 1 5;1  9(3):246–252
0. Stiefel U, Paterson DL, Pultz NJ, Gordon SM, Aron DC, Donskey
CJ.  Effect of the increasing use of piperacillin/tazobactam on
the incidence of vancomycin-resistant enterococci in four
academic medical centers. Infect Control Hosp Epidemiol.
2004;25:380–3.
1. Lautenbach E, LaRosa LA, Marr AM, Nachamkin I, Bilker WB,
Fishman NO. Changes in the prevalence of
vancomycin-resistant enterococci in response to
antimicrobial formulary interventions: impact of progressive
restrictions on use of vancomycin and third-generation
cephalosporins. Clin Infect Dis. 2003;36:440–6.
2. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method
of  classifying prognostic comorbidity in longitudinal studies:
development and validation. J Chronic Dis. 1987;40:373–83.
3. WHO  Collaborating Centre for Drug Statistics and
Methodology [internet]. Guidelines for ATC classiﬁcation and
DDD assignment. Oslo, Norway: WHO; 2013. Available from:
http://www.whocc.no/atcddd
4. Marra AR, de Almeida SM, Correa L, et al. The effect of
limiting antimicrobial therapy duration on antimicrobial
resistance in the critical care setting. Am J Infect Control.
2009;37:204–9.
5. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC,
Vandenbroucke JP. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement:
guidelines for reporting observational studies. Ann Intern
Med. 2007;147:573–7.
6. Anderson DJ, Moehring RW, Sloane R, et al. Bloodstream
infections in community hospitals in the 21st century: a
multicenter cohort study. PLOS ONE. 2014;9:e91713.
7. Datta R, Huang SS. Risk of infection and death due to
methicillin-resistant Staphylococcus aureus in long-term
carriers. Clin Infect Dis. 2008;47:176–81.
8. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality
in  bloodstream infections caused by Klebsiella pneumoniae
carbapenemase – producing K. pneumoniae:  importance of
combination therapy. Clin Infect Dis. 2012;55:943–50.
9. Fraser GL, Stogsdill P, Dickens JD Jr, Wennberg DE, Smith RP Jr,
Prato BS. Antibiotic optimization. An evaluation of patient
safety and economic outcomes. Arch Intern Med.
1997;157:1689–94.
0. Solomon DH, Van Houten L, Glynn RJ, et al. Academic
detailing to improve use of broad-spectrum antibiotics at an
academic medical center. Arch Intern Med.
2001;161:1897–902,
http://dx.doi.org/10.1001/archinte.161.15.1897.
1.  Marwick C, Davey P. Care bundles: the holy grail of infectious
risk management in hospital. Curr Opin Infect Dis.
2009;22:364–9.
2. Society for Healthcare Epidemiology of America, Infectious
Diseases Society of America, Pediatric Infectious Diseases
Society. Policy statement on antimicrobial stewardship by the
Society for Healthcare Epidemiology of America (SHEA), the
Infectious Diseases Society of America (IDSA), and the
Pediatric Infectious Diseases Society (PIDS). Infect Control
Hosp Epidemiol. 2012;33:322–7.
3. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N.
Impact of antimicrobial stewardship in critical care: a
systematic review. J Antimicrob Chemother. 2011;66:1223–30.
4. McGowan JE Jr. Antimicrobial stewardship – the state of the
art in 2011: focus on outcome and methods. Infect Control
Hosp Epidemiol. 2012;33:331–7.
5. Charani E, Edwards R, Sevdalis N, et al. Behavior change
strategies to inﬂuence antimicrobial prescribing in acute care:
a  systematic review. Clin Infect Dis. 2011;53:651–62.
